Adjusted EBITDA was negative $5 million, improving $8 million year-over-year and $19 million sequentially.
Cash and cash equivalents plus restricted cash totaled $134 million at quarter-end, down from $171 million at year-end 2024.
DDD reported Q2 2025 consolidated revenue of $95 million, down 16% year-over-year and 11% excluding the divested Geomagic software business.
GAAP net income was $104 million, driven by gains from the Geomagic asset sale and debt repayment, resulting in GAAP EPS of $0.57.
Healthcare Solutions revenue decreased 8% year-over-year, with Dental down 3% and MedTech growing 13%.
Industrial Solutions revenue declined 23% year-over-year, or 13% excluding Geomagic, driven by softness in consumer-facing markets but partially offset by Aerospace and Defense growth.
Non-GAAP gross margin was 39%, slightly down from 41% the prior year, boosted by a $2 million milestone recognition in Regenerative Medicine.
Non-GAAP loss per share improved to $0.07 from $0.14 in the prior year.
Non-GAAP operating expenses were $47 million, down 27% year-over-year and 24% sequentially due to restructuring and cost efficiencies.
Sequential revenue grew 8% when adjusting for the Geomagic divestiture.